BACKGROUND: With an ageing population, older persons become a larger part of the hospital population. The incidence of delirium is high in this group, and experiencing delirium has major short- and long-term sequelae, which makes prevention crucial. During delirium, a disruption of the sleep-wake cycle is frequently observed. Melatonin plays an important role in the regulation of the sleep-wake cycle, so this raised the hypothesis that alterations in the metabolism of melatonin might play an important role in the development of delirium. The aim of this article is to describe the design of a randomised, placebo controlled double-blind trial that is currently in progress and that investigates the effects of melatonin versus placebo on delirium in older, postoperative hip fracture patients. METHODS/ DESIGN:Acutely hospitalised patients aged 65 years or older admitted for surgical repair of hip fracture are randomised (n=452) into a treatment or placebo group. Prophylactic treatment consists of orally administered melatonin (3 mg) at 21:00 h on five consecutive days. The primary outcome is the occurrence of delirium, to be diagnosed according to the Confusion Assessment Method, within eight days after start of the study medication. Secondary outcomes are delirium severity, measured by the Delirium Rating Scale; duration of delirium; differences in subtypes of delirium; differences in total length of hospital stay; total dose of antipsychotics and/or benzodiazepine use during delirium; and in-hospital complications. In the twelve-month follow up visit, cognitive function is measured by a Mini-Mental state examination and the Informant Questionnaire on Cognitive Decline in the Elderly. Functional status is assessed with the Katz ADL index score (patient and family version) and grip strength measurement. The outcomes of these assessments are compared to the outcomes that were obtained during admission. DISCUSSION: The proposed study will contribute to our knowledge because studies on the prophylactic treatment of delirium with long term follow up remain scarce. The results may lead to a prophylactic treatment for frail older persons at high risk for delirium that is safe, effective, and easily implementable in daily practice. TRIAL REGISTRATION: Dutch Clinical Trial Registry: NTR1576.
RCT Entities:
BACKGROUND: With an ageing population, older persons become a larger part of the hospital population. The incidence of delirium is high in this group, and experiencing delirium has major short- and long-term sequelae, which makes prevention crucial. During delirium, a disruption of the sleep-wake cycle is frequently observed. Melatonin plays an important role in the regulation of the sleep-wake cycle, so this raised the hypothesis that alterations in the metabolism of melatonin might play an important role in the development of delirium. The aim of this article is to describe the design of a randomised, placebo controlled double-blind trial that is currently in progress and that investigates the effects of melatonin versus placebo on delirium in older, postoperative hip fracturepatients. METHODS/ DESIGN: Acutely hospitalised patients aged 65 years or older admitted for surgical repair of hip fracture are randomised (n=452) into a treatment or placebo group. Prophylactic treatment consists of orally administered melatonin (3 mg) at 21:00 h on five consecutive days. The primary outcome is the occurrence of delirium, to be diagnosed according to the Confusion Assessment Method, within eight days after start of the study medication. Secondary outcomes are delirium severity, measured by the Delirium Rating Scale; duration of delirium; differences in subtypes of delirium; differences in total length of hospital stay; total dose of antipsychotics and/or benzodiazepine use during delirium; and in-hospital complications. In the twelve-month follow up visit, cognitive function is measured by a Mini-Mental state examination and the Informant Questionnaire on Cognitive Decline in the Elderly. Functional status is assessed with the Katz ADL index score (patient and family version) and grip strength measurement. The outcomes of these assessments are compared to the outcomes that were obtained during admission. DISCUSSION: The proposed study will contribute to our knowledge because studies on the prophylactic treatment of delirium with long term follow up remain scarce. The results may lead to a prophylactic treatment for frail older persons at high risk for delirium that is safe, effective, and easily implementable in daily practice. TRIAL REGISTRATION: Dutch Clinical Trial Registry: NTR1576.
Authors: M S Albert; S E Levkoff; C Reilly; B Liptzin; D Pilgrim; P D Cleary; D Evans; J W Rowe Journal: J Geriatr Psychiatry Neurol Date: 1992 Jan-Mar Impact factor: 2.680
Authors: Joost Witlox; Lisa S M Eurelings; Jos F M de Jonghe; Kees J Kalisvaart; Piet Eikelenboom; Willem A van Gool Journal: JAMA Date: 2010-07-28 Impact factor: 56.272
Authors: Barbara C van Munster; Johanna C Korevaar; Aeilko H Zwinderman; Marcel Levi; W Joost Wiersinga; Sophia E De Rooij Journal: J Am Geriatr Soc Date: 2008-08-04 Impact factor: 5.562
Authors: Tianjing Li; L Susan Wieland; Esther Oh; Karin J Neufeld; Nae-Yuh Wang; Kay Dickersin; Frederick E Sieber Journal: Clin Trials Date: 2017-01-09 Impact factor: 2.486
Authors: M T Blom; S Jansen; A de Jonghe; B C van Munster; A de Boer; S E de Rooij; H L Tan; N van der Velde Journal: J Nutr Health Aging Date: 2015-05 Impact factor: 4.075
Authors: Annemarieke de Jonghe; Barbara C van Munster; J Carel Goslings; Peter Kloen; Carolien van Rees; Reinder Wolvius; Romuald van Velde; Marcel Levi; Rob J de Haan; Sophia E de Rooij Journal: CMAJ Date: 2014-09-02 Impact factor: 8.262
Authors: F Eduardo Martinez; Matthew Anstey; Andrew Ford; Brigit Roberts; Miranda Hardie; Robert Palmer; Lynn Choo; David Hillman; Michael Hensley; Erin Kelty; Kevin Murray; Bhajan Singh; Bradley Wibrow Journal: Trials Date: 2017-01-06 Impact factor: 2.279